<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        17-972-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LINDYNETTE 0.075/0.03 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ETHINYLESTRADIOL, GESTODENE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.03, 0.075
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        63
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        55.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GEDEON RICHTER PLC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GEDEON RICHTER PLC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AA10 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lindynette 75 micrograms / 30 micrograms coated tables
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                75 micrograms of gestodene and 30 micrograms of ethinylestradiol in each coated tablet. 
Excipients with known effect: The preparation also contains 37.17 mg lactose monohydrate and19.66 mg sucrose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablets: yellow, round, biconvex sugar-coated tablets both sides are without imprinting.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Oral contraception.</p><p style="text-align:justify">The decision to prescribe Lindynette should take into consideration the individual woman&rsquo;s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lindynette compares with other combined hormonal contraceptives (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pregnancy should be excluded before starting Lindynette.</p><p style="text-align:justify">The tablets must be taken every day at about the same time, in the order directed on the package. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet- free interval during which time withdrawal bleeding occurs. This usually starts on day 2-3 after the&nbsp;&nbsp; last tablet and may not have finished before the next pack is started.</p><p style="text-align:justify"><strong>How to start Lindynette</strong></p><p style="text-align:justify"><u>No hormonal contraceptive use within the preceding month</u></p><p style="text-align:justify">The user should begin taking Lindynette on Day 1 of her natural menstrual cycle (i.e. the first day of menstrual bleeding). Beginning Lindynette use on days 2-7 of the menstrual cycle (e.g. starting on a Sunday) is also allowed; however a non-hormonal back-up method of birth control [e.g. condoms and spermicide] is recommended during the first 7 days of Lindynette use.</p><p style="text-align:justify"><u>Switching from another combined contraceptive (combined hormonal contraceptive /CHC/, vaginal</u> <u>ring or transdermal patch)</u></p><p style="text-align:justify">Lindynette use should begin preferably on the day after the last active tablet of the previous combined oral contraceptive, but no later than the day following the usual tablet-free or inactive tablet interval of the previous combined oral contraceptive.</p><p style="text-align:justify">In case a vaginal ring or transdermal patch has been used the woman should start using Lindynette preferably on the day of removal, but at the latest when the next application would have been due.</p><p style="text-align:justify"><u>Switching from a progestin-only method of birth control (pill, implant, intrauterine device [IUD],</u> <u>injection)</u></p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The user may discontinue use of a progestin-only pill on any day; use of Lindynette should begin the following day.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lindynette use should begin on the same day that a progestin-only implant or a progestin-only IUD is removed.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lindynette use should begin on the day that the next progestin-only injection is scheduled.</p><p style="text-align:justify">In each of these situations, the user should be advised to use a non-hormonal back-up method of birth control during the first 7 days of Lindynette use.</p><p style="text-align:justify"><u>Following first trimester abortion</u></p><p style="text-align:justify">The woman may start Lindynette immediately. When doing so, she need not take additional contraceptive measures.</p><p style="text-align:justify"><u>Post-partum period</u></p><p style="text-align:justify">Because the immediate post-partum period is associated with an increased risk of thromboembolism, Lindynette should begin no sooner than day 28<sup>th</sup> postpartum day after delivery by non-lactating women or after second-trimester abortion. The woman should be advised to additionally use a non- hormonal back-up method for the first 7 days of tablet taking. However, if intercourse has already taken place, pregnancy should be excluded before the actual start of Lindynette use or the woman has to wait for her first menstrual period before beginning Lindynette use (see also sections 4.4 and 4.6).</p><p style="text-align:justify">Management of missed tablets</p><p style="text-align:justify">Contraceptive protection may be reduced if tablets are missed and particularly if the missing of tablets extends the tablet-free interval.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provided that the user is less than 12 hours late in taking a tablet, she should take it as soon as she remembers and further tablets should be taken at the usual time.</p><p style="text-align:justify">If she is <strong>more than 12 hours late </strong>in taking the last missed tablet, contraceptive protection may be reduced. The management of missed tablets can be guided by the following two basic rules:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet-taking must never be discontinued for longer than 7 days.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7 days of uninterrupted tablet-taking are required to attain adequate suppression of the hypothalamic-pituitary-ovarian-axis.</p><p style="text-align:justify">Accordingly the following advice can be given in daily practice:</p><p style="text-align:justify"><strong>Week 1</strong></p><p style="text-align:justify">The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. In addition, a barrier method such as a condom should be used for the next 7 days. If intercourse took place in the preceding 7 days, the possibility of a pregnancy should be considered. The more tablets are missed and the closer they are to the regular tablet-free interval, the higher the risk of a pregnancy.</p><p style="text-align:justify"><strong>Week 2</strong></p><p style="text-align:justify">The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. Provided that the woman has taken her tablets correctly in the 7 days preceding the missed tablet, there is no need to use extra contraceptive precautions. However, if this is not the case or she has missed more than 1 tablet, the woman should be advised to use extra precautions for 7 days.</p><p style="text-align:justify"><strong>Week 3</strong></p><p style="text-align:justify">The risk of reduced reliability is imminent because of the forthcoming tablet-free interval. However, by adjusting the tablet-intake schedule, reduced contraceptive protection can still be prevented. By adhering to either of the following two options, there is therefore no need to use extra contraceptive precautions, provided that in the 7 days preceding the missed tablet the woman has taken all tablets correctly. If this is not the case, she should follow the first of these two options and use extra precautions for the next 7 days as well.</p><p style="text-align:justify"><!--[if gte vml 1]><v:rect id="_x0000_s1027" style='position:absolute;
 margin-left:441.05pt;margin-top:48pt;width:154.25pt;height:696.1pt;z-index:251660288;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 fillcolor="#f1f1f1" stroked="f">
 <w:wrap anchorx="page" anchory="page"/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td style="text-align:justify">&nbsp;</td></tr><tr><td style="text-align:justify">&nbsp;</td><td style="text-align:justify">&nbsp;</td></tr></tbody></table><p style="text-align:justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. The next blister pack must be started as soon as the current blister pack is finished, i.e., no gap should be left between packs. The user is unlikely to have withdrawal bleeding until the end of the second pack, but she may experience spotting or breakthrough bleeding on tablet-taking days.</p><p style="text-align:justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The woman may also be advised to discontinue tablet-taking from the current blister pack. She should then have a tablet-free interval of up to 7 days, including the days she missed tablets, and subsequently continue with the next blister pack.</p><p style="text-align:justify">If the woman missed tablets and subsequently has no withdrawal bleeding in the first normal tablet- free interval, the possibility of a pregnancy should be considered.</p><p style="text-align:justify">Measures to be taken in case of vomiting and/or diarrhoea</p><p style="text-align:justify">If vomiting or diarrhoea occurs within 4 hours after the tablet taking, tablet absorption may be incomplete. Use of tablets from a spare pack is required, as outlined in the section &ldquo;Management of missed tablets&rdquo;.</p><p style="text-align:justify">The necessary active tablets should be taken from a spare pack.</p><p style="text-align:justify"><strong>How to advance or delay a menstruation</strong></p><p style="text-align:justify">To delay a period the woman should continue with another pack of Lindynette without a tablet-free interval. The extension can be carried on for as long as wished until the end of the second pack.</p><p style="text-align:justify">During the extension the woman may experience breakthrough bleeding or spotting. Regular intake of Lindynette is then resumed after the usual 7 day tablet-free interval.</p><p style="text-align:justify">To move menstruation to a weekday other than that on which the woman is used to having it under the current tablet schedule, she can be advised to shorten the next tablet-free period by as many days as&nbsp; she wishes. The shorter the pause, the higher the risk that she will not get her menstruation and will have withdrawal bleeding or spotting while she is taking the next pack (which is also true when menstruation is being delayed).</p><p style="text-align:justify"><u>Special populations</u></p><p style="text-align:justify"><em><u>Paediatric population and adolescents</u></em></p><p style="text-align:justify">Lindynette is indicated only after the first menstrual period. No data are available which would suggest dose modification.</p><p style="text-align:justify"><em><u>Elderly</u></em></p><p style="text-align:justify">Not applicable. Lindynette is not indicated after the menopause.</p><p style="text-align:justify"><em><u>Hepatic impairment</u></em></p><p style="text-align:justify">Lindynette is contraindicated in women with hepatic impairment (see section 4.3).</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Combined hormonal contraceptives (CHCs) should not be used in the following conditions:
-	Presence or risk of venous thromboembolism (VTE)
-	Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
-	Known hereditary or acquired predisposition for venous thromboembolism, such as APC- resistance (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
-	Major surgery with prolonged immobilisation (see section 4.4).
-	A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4).
 




-	Presence or risk of arterial thromboembolism (ATE)
-	Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris).
-	Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA).
-	Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
-	History of migraine with focal neurological symptoms.
-	A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
-	diabetes mellitus with vascular symptoms
-	severe hypertension
-	severe dyslipoproteinaemia
-	Presence or history of pancreatitis associated with severe hypertriglyceridaemia.
-	Presence or history of serious hepatic disorders (as long as liver function tests are not normalized).
-	Presence or history of liver tumours (benign or malignant).
-	Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts).
-	Undiagnosed abnormal vaginal bleeding.
-	Known or suspected pregnancy.
-	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em><u>Warnings</u></em></p><p style="text-align:justify">If any of the conditions or risk factors mentioned below is present, the suitability of Lindynette should be discussed with the woman.</p><p style="text-align:justify">In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Lindynette should be discontinued.</p><p style="text-align:justify"><strong>Risk of venous thromboembolism (VTE)</strong></p><p style="text-align:justify">The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use. <strong>Products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE. Other products such as Lindynette may have up to twice this level of risk. The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with Lindynette, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.</strong></p><p style="text-align:justify">In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).</p><p style="text-align:justify">It is estimated<sup>1</sup> that out of 10,000 women who use a CHC containing gestodene between 9 and 12 women will develop a VTE in one year; this compares with about 6<sup>2</sup> in women who use a levonorgestrel-containing CHC.</p><p style="text-align:justify">1 These incidences were estimated from the totality of the epidemiological study data, using relative risks for the different products compared with levonorgestrel-containing CHCs.</p><p style="text-align:justify">2 Mid-point of range of 5-7 per 10,000 WY, based on a relative risk for CHCs containing levonorgestrel versus non-use of approximately 2.3 to 3.6.</p><p style="text-align:justify"><!--[if gte vml 1]><v:rect id="_x0000_s1026" style='position:absolute;
 margin-left:441.05pt;margin-top:48pt;width:154.25pt;height:696.1pt;z-index:-252784640;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 fillcolor="#f1f1f1" stroked="f">
 <w:wrap anchorx="page" anchory="page"/>
</v:rect><![endif]-->In both cases, the number of VTEs per year is fewer than the number expected during pregnancy or in the postpartum period.</p><p style="text-align:justify">VTE may be fatal in 1-2% of cases.</p><p style="text-align:justify"><strong>Number of VTE events per 10,000 women in one year</strong></p><p style="text-align:justify"><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1032" type="#_x0000_t75"
  style='position:absolute;margin-left:58.6pt;margin-top:10.4pt;width:387.95pt;
  height:218.6pt;z-index:5;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/AJA-50~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><p style="text-align:justify"><img alt="" width="744" height="415" src="data:image/jpeg;base64,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" /></p><p style="text-align:justify">Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.</p><p style="text-align:justify"><strong>Risk factors for VTE</strong></p><p style="text-align:justify">The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).</p><p style="text-align:justify">Lindynette is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors &ndash; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p style="text-align:justify">Table: Risk factors for VTE</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p style="text-align:justify"><strong>Risk factor</strong></p></td><td><p style="text-align:justify"><strong>Comment</strong></p></td></tr><tr><td><p style="text-align:justify">Obesity (body mass index over 30 kg/m&sup2;)</p></td><td><p style="text-align:justify">Risk increases substantially as BMI rises.</p><p style="text-align:justify">Particularly important to consider if other risk factors also present.</p></td></tr><tr><td><p style="text-align:justify">Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify">Note: temporary immobilisation</p></td><td><p style="text-align:justify">In these situations it is advisable to discontinue use of the patch/pill/ring (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.</p><p style="text-align:justify">Antithrombotic treatment should be considered if Lindynette has not been discontinued in advance.</p></td></tr></tbody></table><p style="text-align:justify">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p style="text-align:justify">including air travel &gt;4 hours can also</p><p style="text-align:justify">be a risk factor for VTE, particularly in women with other risk factors</p></td><td><p style="text-align:justify">&nbsp;</p></td></tr><tr><td><p style="text-align:justify">Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early</p><p style="text-align:justify">age e.g. before 50).</p></td><td><p style="text-align:justify">If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use</p></td></tr><tr><td><p style="text-align:justify">Other medical conditions associated with VTE</p></td><td><p style="text-align:justify">Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn&rsquo;s disease or ulcerative colitis) and sickle cell</p><p style="text-align:justify">disease</p></td></tr><tr><td><p style="text-align:justify">Increasing age</p></td><td><p style="text-align:justify">Particularly above 35 years</p></td></tr></tbody></table><p style="text-align:justify">There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.</p><p style="text-align:justify">The increased risk of thromboembolism in pregnancy, and particularly the 6 week period of the puerperium, must be considered (for information on &ldquo;Fertility, pregnancy and lactation&rdquo; see section 4.6).</p><p style="text-align:justify"><strong><u>Symptoms of VTE (deep vein thrombosis and pulmonary embolism)</u></strong></p><p style="text-align:justify">In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p style="text-align:justify">Symptoms of deep vein thrombosis (DVT) can include:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unilateral swelling of the leg and/or foot or along a vein in the leg;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or tenderness in the leg which may be felt only when standing or walking;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased warmth in the affected leg; red or discoloured skin on the leg.</p><p style="text-align:justify">Symptoms of pulmonary embolism (PE) can include:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden onset of unexplained shortness of breath or rapid breathing;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden coughing which may be associated with haemoptysis;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sharp chest pain;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe light headedness or dizziness;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeat.</p><p style="text-align:justify">Some of these symptoms (e.g. &ldquo;shortness of breath&rdquo;, &ldquo;coughing&rdquo;) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).</p><p style="text-align:justify">Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity.</p><p style="text-align:justify">If the occlusion occurs in the eye, symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately</p><p style="text-align:justify"><strong>Risk of arterial thromboembolism (ATE)</strong></p><p style="text-align:justify">Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.</p><p style="text-align:justify"><strong><u>Risk factors for ATE</u></strong></p><p style="text-align:justify">The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Lindynette is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see</p><p style="text-align:justify">section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).&nbsp;</p><p style="text-align:justify">Table: Risk factors for ATE</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p style="text-align:justify"><strong>Risk factor</strong></p></td><td><p style="text-align:justify"><strong>Comment</strong></p></td></tr><tr><td><p style="text-align:justify">Increasing age</p></td><td><p style="text-align:justify">Particularly above 35 years</p></td></tr><tr><td><p style="text-align:justify">Smoking</p></td><td><p style="text-align:justify">Women should be advised not to smoke if they wish to use a CHC. Women over 35 who continue to smoke should be strongly advised to use a different method of</p><p style="text-align:justify">contraception.</p></td></tr><tr><td><p style="text-align:justify">Hypertension</p></td><td><p style="text-align:justify">&nbsp;</p></td></tr><tr><td><p style="text-align:justify">Obesity (body mass index over 30 kg/m<sup>2</sup>)</p></td><td><p style="text-align:justify">Risk increases substantially as BMI increases.</p><p style="text-align:justify">Particularly important in women with additional risk factors</p></td></tr><tr><td><p style="text-align:justify">Positive family history (arterial thromboembolism ever in a sibling or parent especially at relatively early</p><p style="text-align:justify">age e.g. below 50).</p></td><td><p style="text-align:justify">If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use</p></td></tr><tr><td><p style="text-align:justify">Migraine</p></td><td><p style="text-align:justify">An increase in frequency or severity of migraine during CHC use (which may be prodromal of a</p><p style="text-align:justify">cerebrovascular event) may be a reason for immediate discontinuation</p></td></tr><tr><td><p style="text-align:justify">Other medical conditions associated with adverse vascular events</p></td><td><p style="text-align:justify">Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia</p><p style="text-align:justify">and systemic lupus erythematosus.</p></td></tr></tbody></table><p style="text-align:justify"><strong><u>Symptoms of ATE</u></strong></p><p style="text-align:justify">In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p style="text-align:justify">Symptoms of a cerebrovascular accident can include:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden numbness or weakness of the face, arm or leg, especially on one side of the body;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble walking, dizziness, loss of balance or coordination;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden confusion, trouble speaking or understanding;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden trouble seeing in one or both eyes;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden, severe or prolonged headache with no known cause;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of consciousness or fainting with or without seizure.</p><p style="text-align:justify">Temporary symptoms suggest the event is a transient ischaemic attack (TIA).</p><p style="text-align:justify">Symptoms of myocardial infarction (MI) can include:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discomfort radiating to the back, jaw, throat, arm, stomach;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of being full, having indigestion or choking;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating, nausea, vomiting or dizziness;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; extreme weakness, anxiety, or shortness of breath;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid or irregular heartbeats.</p><p style="text-align:justify"><em>Tumours</em></p><p style="text-align:justify">The most important risk factor for cervical cancer is the presence of human papillomavirus (HPV) infection. Some studies suggest that long-term CHC use has been associated with an increase in the risk of the development of cervical cancer in women infected with the human papilloma virus.</p><p style="text-align:justify">However, there is still controversy about the extent to which this finding is influenced by confounding effects (e.g. cervical cancer examination or the sexual behaviour of the user of mechanical contraceptive measures).</p><p style="text-align:justify">A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined oral contraceptives. The excess risk gradually disappears during the course of the 10 years after cessation of combined oral contraceptive use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent combined oral contraceptive users is small in relation to the overall risk of breast cancer. These studies do not provide evidence for causation.</p><p style="text-align:justify">The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in combined oral contraceptive users, the biological effects of combined oral contraceptives or a combination of both. Breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users.</p><p style="text-align:justify">In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of combined oral contraceptives. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking oral contraceptives.</p><p style="text-align:justify"><em>Other conditions</em></p><p style="text-align:justify">Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using combined oral contraceptives.</p><p style="text-align:justify">Although small increases in blood pressure have been reported in many women taking combined oral contraceptives, clinically relevant increases are rare. Nevertheless, in these rare cases an immediate discontinuation of combined oral contraceptive use is justified, and antihypertensive treatment should be started. Where considered appropriate by the physician, combined oral contraceptive use may be resumed if normotensive values can be achieved with antihypertensive therapy.</p><p style="text-align:justify">The following diseases/conditions have been reported to occur or deteriorate with both pregnancy and combined oral contraceptive use, but the evidence of an association with combined oral contraceptive use is inconclusive: jaundice and/or pruritus related to cholestasis; gallstones; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham&#39;s chorea; herpes gestationis; otosclerosis-related hearing loss.</p><p style="text-align:justify">In women with hereditary angioedema exogenous oestrogens may induce or exacerbate symptoms of angioedema.</p><p style="text-align:justify">Acute or chronic disturbances of liver function may necessitate the discontinuation of combined oral contraceptive use until markers of liver function return to normal. The metabolism of steroid hormones can significantly decrease in case of impaired liver function.</p><p style="text-align:justify">Recurrence of cholestatic jaundice which previously occurred during pregnancy or during previous use of sex steroids necessitates the discontinuation of oral contraceptives.</p><p style="text-align:justify">Although combined oral contraceptives may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using low-dose combined oral contraceptives (containing &lt; 0.05 mg ethinylestradiol). However, diabetic women should be carefully observed, particularly in the early stage of oral contraceptive use.</p><p style="text-align:justify">The development of Crohn&#39;s disease and ulcerative colitis has been reported during combined oral contraceptive use.</p><p style="text-align:justify">Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking combined oral contraceptives.</p><p style="text-align:justify">Women with a history of depression who use combined oral contraceptives should be carefully observed and the medicine discontinued if depression recurs to a serious degree. Patients becoming significantly depressed while taking combined oral contraceptives should stop the medication and use an alternate method of contraception in an attempt to determine whether the symptom is drug-related.&nbsp;</p><p style="text-align:justify">Precautions for use</p><p style="text-align:justify"><strong>Medical examinations/consultation</strong></p><p style="text-align:justify">Prior to the initiation or reinstitution of Lindynette a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contra-indications (see section 4.3) and warnings (see section 4.4). It is important to draw a woman&rsquo;s attention to the information on venous and arterial thrombosis, including the risk of Lindynette compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.</p><p style="text-align:justify">The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given. The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.</p><p style="text-align:justify">Women should be advised that oral contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases.</p><p style="text-align:justify">REDUCED EFFICACY</p><p style="text-align:justify">The efficacy of combined oral contraceptives may be reduced in the event of e.g. missed tablets (see section 4.2), gastrointestinal disturbances (see section 4.2) or concomitant medication (see</p><p style="text-align:justify">section 4.5).</p><p style="text-align:justify">REDUCED CYCLE CONTROL</p><p style="text-align:justify">With all CHCs, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles.</p><p style="text-align:justify">If bleeding irregularities persist or occur after previously regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude pregnancy or malignancy. These may include curettage.</p><p style="text-align:justify">In some women withdrawal bleeding may not occur during the tablet-free interval.</p><p style="text-align:justify">If the pill has been taken according to the directions described in section 4.2, it is unlikely that the woman is pregnant. However, if the pill has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before oral contraceptive use is continued.</p><p style="text-align:justify"><u>Paediatric population</u></p><p style="text-align:justify">The safety and efficacy of combined oral contraceptives have been established in adult women of reproductive age. The use of such preparations before the menarche is not indicated.</p><p style="text-align:justify"><u>Elderly</u></p><p style="text-align:justify">The use of combined oral contraceptives in menopausal women is not indicated.</p><p style="text-align:justify">This medicinal product contains lactose and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, lactose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.</p><p style="text-align:justify"><u>Effects of other medicinal products on Lindynette</u></p><p style="text-align:justify">Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones and which may lead to breakthrough bleeding and/or contraceptive failure.</p><p style="text-align:justify"><em>Management</em></p><p style="text-align:justify">Enzyme induction can already be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks. After the cessation of drug therapy enzyme induction may be sustained for about 4 weeks.</p><p style="text-align:justify"><em>Short-term treatment</em></p><p style="text-align:justify">Women on treatment with enzyme inducing drugs should temporarily use a barrier method or another method of contraception in addition to the COC. The barrier method must be used during the whole time of the concomitant drug therapy and for 28 days after its discontinuation. If the drug therapy runs beyond the end of the tablets in the COC pack, the next COC pack should be started right after the previous one without the usual tablet-free interval.</p><p style="text-align:justify"><em>Long-term treatment</em></p><p style="text-align:justify">In women on long-term treatment with enzyme-inducing active substances, another reliable, non- hormonal, method of contraception is recommended.</p><p style="text-align:justify">The following interactions have been reported in the literature.</p><p style="text-align:justify"><em>Substances increasing the clearance of COCs (diminished efficacy of COCs by enzyme-induction), e.g </em>Barbiturates, bosentan, carbamazepine, phenytoin, primidone, phenylbutazone, dexamethasone, rifampicin, rifabutin, and HIV medication ritonavir, nevirapine and efavirenz and possibly also felbamate, griseofulvin, oxcarbazepine, topiramate, modafinil and products containing the herbal remedy St. John&#39;s Wort (<em>Hypericum perforatum</em>).</p><p style="text-align:justify"><em>Substances with variable effects on the clearance of COCs</em></p><p style="text-align:justify">When co-administered with COCs, many combinations of HIV protease inhibitors and non- nucleoside, reverse transcriptase inhibitors, including combinations with HCV inhibitors can increase or decrease, plasma concentrations of estrogen or progestins. The net effect of these changes may be clinically, relevant in some cases.</p><p style="text-align:justify">Therefore, the prescribing information of concomitant HIV/HCV medications should be consulted to identify potential interactions and any related recommendations. In case of any doubt, an additional barrier contraceptive method should be used by women on protease inhibitor or non-nucleoside reverse transcriptase inhibitor therapy.</p><p style="text-align:justify">Other examples of substances that may decrease serum EE concentrations:</p><p style="text-align:justify">Any substance that reduces gastrointestinal transit time and, as a consequence of this, absorption (e.g. laxatives).</p><p style="text-align:justify">Examples of substances that may increase serum EE concentrations:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atorvastatin,</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; competitive inhibitors for sulfation in the gastrointestinal wall, such as ascorbic acid (vitamin C) and paracetamol (acetaminophen),</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; substances that inhibit cytochrome P450 3A4 isoenzymes such as indinavir, fluconazole, voriconazole and troleandomycin.</p><p style="text-align:justify"><u>Effects of Lindynette on other medicinal products</u></p><p style="text-align:justify">Oral contraceptives may affect the metabolism of certain other active substances. Accordingly, plasma, and tissue concentrations may either increase (e.g. ciclosporin, theophylline, corticosteroids) or decrease (e.g. lamotrigine, valproat).</p><p style="text-align:justify">Tizanidine</p><p style="text-align:justify">Peroral contraception can increase the blood pressure reducing effect of tizanidine due to an inhibition of tizanidines release in CYP1A2. Exercise caution when prescribing to users of contraceptive pills, due to tizanidine&#39;s limited therapeutic interval.</p><p style="text-align:justify">Levothyroxine</p><p style="text-align:justify">Estrogen therapy can lead to a reduction of free thyroxine as well as an increase of TSH in hypothyroid women in treatment with levothyroxine.</p><p style="text-align:justify">The combination can be used with a dosage adjustment. <u>Other forms of interactions</u></p><p style="text-align:justify">Troleandomycin may increase the risk of intrahepatic cholestasis during co-administration with combined oral contraceptives.</p><p style="text-align:justify">In patients treated with flunarizine, use of oral contraceptives has been reported to increase the risk of galactorrhoea.</p><p style="text-align:justify">The prescribing information of concomitant medications should be consulted to identify potential interactions.</p><p style="text-align:justify">Interactions with laboratory tests</p><p style="text-align:justify">The use of combined oral contraceptives can cause certain physiological alterations affecting the results of some laboratory tests, including:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; biochemical parameters of liver function (including a decrease in bilirubin and alkaline phosphatase), thyroid function (increased total T<sub>3</sub> and T<sub>4</sub> due to increased TBG (thyroxin- binding globulin), decreased free T<sub>3</sub> resin uptake), adrenal function (increased plasma cortisol, increased cortisol binding globulin, decreased dehydroepiandrosterone sulfate /DHEAS/), and renal function (increased plasma creatinine and creatinine clearance)</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plasma levels of (carrier) proteins, such as corticosteroid-binding globulin and lipid/lipoprotein fractions</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parameters of carbohydrate metabolism</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parameters of coagulation and fibrinolysis</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased serum folate levels</p><p style="text-align:justify">Changes generally remain within the normal laboratory range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Pregnancy</u></p><p style="text-align:justify">Lindynette is not indicated during pregnancy.</p><p style="text-align:justify">Pregnancy must be ruled out before contraception with Lindynette is initiated.</p><p style="text-align:justify">If pregnancy occurs during medication with Lindynette, the preparation should be withdrawn immediately (see section 4.3).</p><p style="text-align:justify">Data on pregnancies exposed to gestodene are rather limited to permit conclusions concerning negative effects of gestodene on pregnancy, health of the foetus or neonate. Until now, no relevant epidemiological data are available.</p><p style="text-align:justify">The increased risk of VTE during the postpartum period should be considered when re-starting Lindynette (see sections 4.2 and 4.4).</p><p style="text-align:justify"><u>Breast-feeding</u></p><p style="text-align:justify">Small amounts of contraceptive steroids and/or metabolites have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement.</p><p style="text-align:justify">Oral contraception may influence lactation, as their use may reduce the quantity and change the composition of breast milk.</p><p style="text-align:justify">The use of combined oral contraceptives is generally not recommended until the nursing mother has completely weaned her child.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lindynette has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The undesirable effects listed in the table are defined according to the following frequency convention: Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&sup3;1/10)</p><ul><li style="text-align: justify;">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&sup3;1/100 to &lt;1/10)</li><li style="text-align: justify;">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&sup3;1/1,000 to &lt;1/100)</li><li style="text-align: justify;">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&sup3;1/10,000 to &lt;1/1,000)</li><li style="text-align: justify;">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt;1/10,000)</li><li style="text-align: justify;">Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cannot be estimated from the available data.</li></ul><p style="text-align:justify">Use of combined oral contraceptives has been associated with an increased risk of the following conditions:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arterial and venous thrombotic and thromboembolic events (see also section 4.4)</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cervical intraepithelial neoplasia and cervical cancer</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast cancer</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increased risk of benign hepatic tumours (e.g. focal nodular hyperplasia, hepatic adenoma).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p style="text-align:justify"><strong>System organ class</strong></p></td><td><p style="text-align:justify"><strong>Undesirable effects</strong></p></td></tr><tr><td><p style="text-align:justify"><strong>Infections and infestations</strong></p></td><td><p style="text-align:justify">&nbsp;</p></td></tr><tr><td><p style="text-align:justify">Common</p></td><td><p style="text-align:justify">Vaginitis, including candidiasis</p></td></tr><tr><td colspan="2"><p style="text-align:justify"><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td></tr><tr><td><p style="text-align:justify">Very rare</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Immune system disorders</strong></p></td><td><p style="text-align:justify">Hepatocellular carcinomas</p></td></tr><tr><td><p style="text-align:justify">Rare</p></td><td><p style="text-align:justify">Anaphylactic/anaphylactoid reactions including rare cases of urticaria, angioedema and severe reactions with respiratory and circulatory</p><p style="text-align:justify">symptoms</p></td></tr><tr><td><p style="text-align:justify">Very rare</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Metabolism and nutrition disorders</strong></p></td><td><p style="text-align:justify">Exacerbation of systemic lupus erythematosus</p></td></tr><tr><td><p style="text-align:justify">Uncommon</p></td><td><p style="text-align:justify">Changes in serum lipid levels including</p><p style="text-align:justify">hypertrigliceridaemia; changes in appetite (increase or decrease)</p></td></tr><tr><td><p style="text-align:justify">Rare</p></td><td><p style="text-align:justify">Decrease in serum folate levels*, glucose intolerance</p></td></tr><tr><td><p style="text-align:justify">Very rare</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Psychiatric disorders</strong></p></td><td><p style="text-align:justify">Exacerbation of porphyria</p></td></tr><tr><td><p style="text-align:justify">Common</p></td><td><p style="text-align:justify">Mood changes, including depression Changes in libido</p></td></tr><tr><td><p style="text-align:justify"><strong>Nervous system disorders</strong></p></td><td><p style="text-align:justify">&nbsp;</p></td></tr><tr><td><p style="text-align:justify">Very common</p></td><td><p style="text-align:justify">Headache, including migraine</p></td></tr><tr><td><p style="text-align:justify">Common</p></td><td><p style="text-align:justify">Nervousness; dizziness</p></td></tr><tr><td><p style="text-align:justify">Very rare</p></td><td><p style="text-align:justify">Aggravation of chorea</p></td></tr><tr><td><p style="text-align:justify"><strong>Eye disorders</strong></p></td><td><p style="text-align:justify">&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width:165px"><p style="text-align:justify">Rare</p></td><td style="width:590px"><p style="text-align:justify">Intolerance to contact lenses</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very rare</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Cardiac disorders</strong></p></td><td style="width:590px"><p style="text-align:justify">Optic neuritis**; retinal vascular thrombosis</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Uncommon</p></td><td style="width:590px"><p style="text-align:justify">Hypertension</p></td></tr><tr><td style="width:165px"><p style="text-align:justify"><strong>Vascular disorders</strong></p></td><td style="width:590px"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Rare</p></td><td style="width:590px"><p style="text-align:justify">Venous thromboembolism</p><p style="text-align:justify">Arterial thromboembolism</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very rare</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Gastrointestinal disorders</strong></p></td><td style="width:590px"><p style="text-align:justify">Aggravation of varicose veins</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Common</p></td><td style="width:590px"><p style="text-align:justify">Nausea; vomiting; abdominal pain</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Uncommon</p></td><td style="width:590px"><p style="text-align:justify">Abdominal cramps; bloating</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very rare</p></td><td style="width:590px"><p style="text-align:justify">Pancreatitis; ischaemic colitis</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Not known</p></td><td style="width:590px"><p style="text-align:justify">Inflammatory bowel diseases (Crohn&rsquo;s disease, colitis ulcerative)</p></td></tr><tr><td style="width:165px"><p style="text-align:justify"><strong>Hepatobiliary disorder</strong></p></td><td style="width:590px"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Rare</p></td><td style="width:590px"><p style="text-align:justify">Cholestatic jaundice</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very rare</p></td><td style="width:590px"><p style="text-align:justify">Gallbladder disease, including gallstones***</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Not known</p></td><td style="width:590px"><p style="text-align:justify">Hepatocellular injury (e.g. hepatitis, hepatic function abnormal)</p></td></tr><tr><td style="width:165px"><p style="text-align:justify"><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="width:590px"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Common</p></td><td style="width:590px"><p style="text-align:justify">Acne</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Uncommon</p></td><td style="width:590px"><p style="text-align:justify">Rash; chloasma (melasma) which may persist;</p><p style="text-align:justify">hirsutism; alopecia</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Rare</p></td><td style="width:590px"><p style="text-align:justify">Erythema nodosum</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very rare</p></td><td style="width:590px"><p style="text-align:justify">Erythema multiforme</p></td></tr><tr><td style="width:165px"><p style="text-align:justify"><strong>Renal and urinary disorders</strong></p></td><td style="width:590px"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very rare</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Reproductive system and breast disorders</strong></p></td><td style="width:590px"><p style="text-align:justify">Haemolytic uraemic syndrome</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Very common</p></td><td style="width:590px"><p style="text-align:justify">Breakthrough bleeding/spotting</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Common</p></td><td style="width:590px"><p style="text-align:justify">Breast pain, tenderness, enlargement, secretion; dysmenorrhoea; change in menstrual flow; change in cervical ectropion and secretion; amenorrhoea</p></td></tr><tr><td style="width:165px"><p style="text-align:justify"><strong>General disorders and administration site conditions</strong></p></td><td style="width:590px"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Common</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Investigations</strong></p></td><td style="width:590px"><p style="text-align:justify">Fluid retention/oedema</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Common</p></td><td style="width:590px"><p style="text-align:justify">Changes in weight (increase or decrease)</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Uncommon</p></td><td style="width:590px"><p style="text-align:justify">Increase in blood pressure, changes in serum</p><p style="text-align:justify">lipid levels, including hypertriglycerideamia</p></td></tr><tr><td style="width:165px"><p style="text-align:justify">Rare</p></td><td style="width:590px"><p style="text-align:justify">Decrease in serum folate levels*</p></td></tr></tbody></table><p style="text-align:justify">* Serum folate levels may be depressed by combined oral contraceptive therapy. This may be of clinical significance if the woman becomes pregnant shortly after discontinuing combined oral contraceptive.</p><p style="text-align:justify">** Optic neuritis may lead to partial or complete loss of vision.</p><p style="text-align:justify">*** Combined oral contraceptives may worsen existing gallbladder disease and may accelerate the development of this disease in previously asymptomatic women.</p><p style="text-align:justify"><u>Description of selected adverse reactions</u></p><p style="text-align:justify">An increased risk of arterial and venous thrombotic and thrombo-embolic events, including&nbsp; myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.</p><p style="text-align:justify">In women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema.</p><p style="text-align:justify"><u>Reporting of suspected adverse reactions</u></p><p style="text-align:justify">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It&nbsp; allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system&nbsp;&nbsp; listed in <u>Appendix V.</u></p><p style="text-align:justify">To report any side effect(s):</p><ul><li style="text-align: justify;"><strong>Saudi Arabia:</strong><ul><li>The National Pharmacovigilance Centre (NPC)<ul><li>Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa&nbsp;</li></ul></li></ul></li><li style="text-align: justify;"><strong>Other GCC States:</strong><br />Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Symptoms of oral contraceptive overdosage in adults and children may include nausea, vomiting,&nbsp; breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; withdrawal bleeding may occur in females. There is no specific antidote, and further treatment of overdose, if necessary, is directed to the symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: Progestogens and estrogens, fixed combinations,</p><p style="text-align:justify">ATC code: G03A A10</p><p style="text-align:justify"><u>Mechanism of action</u></p><p style="text-align:justify">Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of action is inhibition of ovulation, other mechanisms including changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation) support the contraceptive effect.</p><p style="text-align:justify">In case of appropriate and continuous intake the probable method failure of combined oral contraceptives is 0.1% per year. At the same time in case of usual administration the overall method failure of combined oral contraceptives is 5% per year. The efficacy of most of the contraceptive methods depends on how reliably they are used. Method failure of combined oral contraceptives is probably due to missed use.</p><p style="text-align:justify">In addition to prevention of pregnancy the CHCs have several positive characteristics, which should&nbsp; be taken into consideration &ndash; together with the undesirable effects &ndash; when choosing a contraceptive method. During CHC use menstrual cycles may become more regular, lighter, and monthly blood loss may be reduced, decreasing the occurrence of anaemia as a consequence of iron deficiency.</p><p style="text-align:justify">It has been established that the risk of endometrial and ovarian cancer is reduced. Furthermore, with the use of higher-dosed combined oral contraceptives (0.05 mg ethinylestradiol) a reduction in the occurrence of ovarian cysts, pelvic inflammatory diseases, benign breast disorders and ectopic pregnancies has been observed. Whether these benefits also apply to lower-dosed combined oral contraceptives remain to be confirmed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Gestodene</em></p><p style="text-align:justify"><u>Absorption</u></p><p style="text-align:justify">Gestodene is rapidly and completely absorbed from gastrointestinal tract. Bioavailability is approximately 99%. Peak serum concentration is reached approximately 1 hour after ingestion.</p><p style="text-align:justify"><u>Distribution</u></p><p style="text-align:justify">In serum gestodene is mainly bound to sex hormone-binding globulin (SHBG) (in 50-70%), and to a lesser extent to serum albumin. Only 1-2% of the total serum concentration of the substance is free steroid. The ethinylestradiol induced increase in SHBG affects the amount of gestodene bound to serum proteins, which causes an increase in the SHBG-bound fraction and a decrease in the albumin- bound fraction. After repeated doses gestodene is accumulated in the plasma. Steady state of the substance is reached in the second half of the cycle, when drug serum concentrations are increased to 3-5-fold.</p><p style="text-align:justify"><u>Biotransformation</u></p><p style="text-align:justify">Gestodene is completely metabolised via the reduction of the C3-ketogroup and the delta-4-double bond and via numerous steps of hydroxylation. It has not been established that gestodene co- administered with ethinylestradiol has any major influence on the kinetics of ethinylestradiol.</p><p style="text-align:justify"><u>Elimination</u></p><p style="text-align:justify">The terminal half-life of gestodene is approximately 16-18 hours. Higher quantity of gestodene metabolites is excreted via the urine than via the faeces.</p><p style="text-align:justify"><em>Ethinylestradiol</em></p><p style="text-align:justify"><u>Absorption</u></p><p style="text-align:justify">Ethinylestradiol is rapidly and completely absorbed from gastrointestinal tract. Bioavailability is approximately 40-60%. Peak serum concentration is reached within 1-2 hours.</p><p style="text-align:justify"><u>Distribution</u></p><p style="text-align:justify">Ethinylestradiol is strongly bound to serum albumin (approximately 98%) and leads to an increase in serum concentration of SHBG. Steady state of the substance is reached in the second half of the cycle, when drug levels in the serum is approximately 30-50% higher than after a single dose.</p><p style="text-align:justify"><u>Biotransformation</u></p><p style="text-align:justify">Ethinylestradiol is subject to presystemic conjugation in both small bowel mucosa and the liver and enters the enterohepatic circulation. The primary oxidation reaction is the 2-hydroxylation carried out by cytochrome P450 enzymes. A wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulfate.</p><p style="text-align:justify"><u>Elimination</u></p><p style="text-align:justify">Ethinylestradiol serum levels fall in two phases. The final disposition phase is characterised by a half- life of approximately 16-18 hours. The metabolites of EE are excreted in a higher quantity in the faeces than in the urine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p style="text-align:justify">However, it must be recalled that sex steroids may promote the growth of certain hormone dependent tissues and tumours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium calcium edetate, Magnesium stearate, Silica colloidal anhydrous, Povidone, Maize starch, Lactose monohydrate, &ldquo;Quinoline&rdquo; Yellow (E 104), Titanium dioxide, Macrogol 6000, Talc, Calcium carbonate, Sucrose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above&nbsp;30&deg;C</p><p>Store&nbsp;in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>21 coated tablets in PVC/PVDC aluminium blister and in a storage bag, in folded carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>